Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.113 EUR | -1.20% | +0.98% | +40.80% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-03 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 4.56B 4.95B 6.77B | Sales 2025 * | 4.34B 4.72B 6.45B | Capitalization | 12.62B 13.72B 18.77B |
---|---|---|---|---|---|
Net income 2024 * | 1.76B 1.92B 2.62B | Net income 2025 * | 1.56B 1.7B 2.32B | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
7.27
x | P/E ratio 2025 * |
7.57
x | Employees | 10,551 |
Yield 2024 * |
5.76% | Yield 2025 * |
6.11% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 day | -1.20% | ||
1 week | +0.98% | ||
Current month | -3.83% | ||
1 month | +5.00% | ||
3 months | +18.66% | ||
6 months | +27.29% | ||
Current year | +40.80% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 15-12-31 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 13-08-31 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 21-01-21 |
James Pettigrew
CHM | Chairman | 65 | 21-10-27 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 16-10-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 5.145 | -0.58% | 0 |
24-06-03 | 5.175 | -3.27% | 1,268 |
24-05-31 | 5.35 | +4.90% | 1,064 |
24-05-30 | 5.1 | 0.00% | 0 |
24-05-29 | 5.1 | +0.10% | 0 |
Delayed Quote Deutsche Boerse AG, June 04, 2024 at 02:10 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.24% | 580B | |
+18.71% | 312B | |
+15.97% | 252B | |
+20.27% | 207B | |
+20.65% | 182B | |
+24.83% | 169B | |
+9.02% | 164B | |
+10.31% | 154B | |
-13.23% | 144B |
- Stock Market
- Equities
- A5G Stock
- A5G Stock